Focused On-demand Library for Ras-related protein Rab-26

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9ULW5

UPID:
RAB26_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9ULW5; B2RAA6; Q3L6K5; Q6NXS7

BACKGROUND:
The Ras-related protein Rab-26 is a key regulator in the cellular logistics system, mediating the transport and secretion of vital molecules. By transitioning between active and inactive states, it recruits downstream effectors essential for vesicle movement and fusion. This protein is crucial for the proper functioning of the Golgi apparatus and the secretion system, impacting the delivery of neurotransmitter receptors to the cell surface and the release of enzymes necessary for digestion.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ras-related protein Rab-26 offers a promising pathway to novel therapeutic interventions. Its central role in membrane trafficking and secretion processes makes it an attractive candidate for drug discovery, aiming to correct or enhance cellular transport mechanisms in disease conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8011 of 8789